16:01 EDT LENZ Therapeutics (LENZ) trading halted, news pending
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LENZ:
- LENZ Therapeutics’ LNZ100 Eye Drop Gains Buy Rating Amid Positive KOL Feedback and Strategic Market Positioning
- Lenz Therapeutics price target raised to $49 from $45 at Citi
- Lenz Therapeutics Prepares for LNZ100 Launch
- LENZ Therapeutics: Positioned for Growth with Strategic Global Expansion and Imminent FDA Approval
- Lenz Therapeutics reports Q2 EPS (53c), consensus (54c)